Latest Stocks: Illumina, Inc. (ILMN) Downgraded by Vetr Inc. to “Buy”

Latest Stocks: Illumina, Inc. (ILMN) Downgraded by Vetr Inc. to “Buy”

Vetr cut shares of Illumina, Inc. (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday morning. They currently have $197.84 price objective on the life sciences company’s stock.

Several other equities analysts have also recently issued reports on ILMN. Cantor Fitzgerald restated a neutral rating and set a $155.00 price objective on shares of Illumina in a research note on Wednesday, February 1st. Leerink Swann raised their price objective on Illumina from $134.00 to $138.00 and gave the stock a market perform rating in a research note on Thursday, February 9th. Canaccord Genuity restated a hold rating and set a $150.00 price objective on shares of Illumina in a research note on Tuesday, February 21st. Evercore ISI upgraded Illumina from a hold rating to a buy rating and set a $190.00 price objective on the stock in a research note on Monday, February 27th. Finally, BTIG Research restated a hold rating on shares of Illumina in a research note on Sunday, March 19th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. Illumina has an average rating of Hold and an average target price of $165.02.

Illumina (NASDAQ:ILMN) opened at 181.51 on Wednesday. The firm has a market capitalization of $26.50 billion, a PE ratio of 36.74 and a beta of 0.79. Illumina has a one year low of $119.37 and a one year high of $189.48. The stock has a 50 day moving average of $180.12 and a 200-day moving average of $160.32.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The firm had revenue of $598 million for the quarter, compared to analysts’ expectations of $590.51 million. During the same period last year, the business posted $0.71 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, equities analysts predict that Illumina will post $3.63 EPS for the current year.

In related news, Director Daniel Bradbury sold 600 shares of the firm’s stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $163.56, for a total transaction of $98,136.00. Following the completion of the transaction, the director now owns 17,065 shares of the company’s stock, valued at $2,791,151.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $172.72, for a total value of $518,160.00. Following the transaction, the director now directly owns 18,704 shares of the company’s stock, valued at approximately $3,230,554.88. The disclosure for this sale can be found here. Insiders have sold 54,666 shares of company stock valued at $9,842,333 in the last ninety days. Company insiders own 1.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Baillie Gifford & Co. boosted its position in shares of Illumina by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 18,766,712 shares of the life sciences company’s stock valued at $2,402,890,000 after buying an additional 178,559 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares in the last quarter. Edgewood Management LLC boosted its position in shares of Illumina by 33.6% in the fourth quarter. Edgewood Management LLC now owns 6,639,776 shares of the life sciences company’s stock valued at $850,157,000 after buying an additional 1,671,293 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Illumina by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,632,576 shares of the life sciences company’s stock valued at $841,554,000 after buying an additional 140,411 shares in the last quarter. 92.79% of the stock is owned by institutional investors and hedge funds. About Illumina

Receive News & Ratings for Illumina Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Illumina Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment